Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00054249 · ClinicalTrials.gov registry record · Phase 2

T900607 in Treating Patients With Gastroesophageal Junction Cancer

A Phase 2 study of Gastric Cancer, sponsored by University Hospitals Seidman Cancer Center.

Completed
Registry status
Phase 2
Development phase
1
Study location

NCT00054249: Completed Phase 2 study of Gastric Cancer, sponsored by University Hospitals Seidman Cancer Center.

NCT00054249 is a Phase 2 study of Gastric Cancer that has completed, run by University Hospitals Seidman Cancer Center. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00054249, a Phase 2 study of Gastric Cancer, has completed, sponsored by University Hospitals Seidman Cancer Center.

COMPLETED
Registry status
Phase 2
Development phase
1
Study location

Study Summary

RATIONALE: Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of T900607 in treating patients who have gastroesophageal junction cancer.

Conditions Studied

Interventions

  • DRUG T900607

Study Locations (1)

Ohio

  • Ireland Cancer Center - Cleveland

Trial Details

FieldValue
Start Date 2002-09
Est. Completion 2010-09
Phase Phase 2

What the finished NCT00054249 record still lists

NCT00054249 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.

The record links to 1 condition, with Gastric Cancer appearing as the primary indexed condition, and to 1 intervention - of which T900607 is the first listed.

NCT00054249 reports a single indexed study location in Ohio.

Frequently Asked Questions

What is clinical trial NCT00054249 about?

NCT00054249 is a clinical study titled "T900607 in Treating Patients With Gastroesophageal Junction Cancer". RATIONALE: Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of T900607 in treating patients who have gastroesophageal junction cancer.

What is the current status of trial NCT00054249?

This trial is currently completed. It is a Phase 2 study. The study started on 2002-09. Estimated completion is 2010-09.

What conditions does trial NCT00054249 study?

This clinical trial studies the following conditions: Gastric Cancer.

What interventions are being tested in trial NCT00054249?

The interventions under investigation include: T900607 (DRUG).

Who is sponsoring clinical trial NCT00054249?

This trial is sponsored by University Hospitals Seidman Cancer Center, which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00054249 being conducted?

This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00054249, the US trial registry maintained by the National Library of Medicine. NCT00054249 (unsized enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.